PBAC's latest decision on Pneumococcal polysaccharide conjugate vaccine, 20-valent: Recommended with restriction (2022). Considered for Prevention of pneumococcal disease in non-Indigenous adults aged ≥70 years, Aboriginal and Torres Strait Islander adults aged ≥25 years, and individuals aged ≥18 years with NIP-listed risk conditions.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2022
Submissions
1
2022 → 2022
Eligible population
Adults aged 18 years and over at increased risk of pneumococcal disease; non-Indigenous adults aged ≥70 years; Aboriginal and Torres Strait Islander adults aged ≥25 years.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Immunogenicity
Comparator
13-valent pneumococcal conjugate vaccine (13vPCV); 15-valent pneumococcal conjugate vaccine (15vPCV); 'no vaccine' for Aboriginal and Torres Strait Islander adults aged 25-49 years
Economic model
Cost-minimisation
ICER note
Cost-minimisation approach used for current NIP populations versus 13vPCV and 15vPCV; ICER values not stated in public document. For expanded population (Aboriginal and Torres Strait Islander adults aged 25-49), cost-effectiveness analysis versus no vaccine presented but specific ICER not disclosed in PSD.